Background Despite the promising results of earlier studies, a clear superiority of drug-
eluting beads transarterial chemoembolization over conventional chemoembolization in …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and third
leading cause of cancer-related mortality worldwide. While surgical resection and …

Background Transarterial chemoembolization (TACE) is the recommended treatment for
intermediate hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …

Background Indications for liver transplantation for hepatocellular carcinoma are evolving
and so-called expanded criteria remain debated. Locoregional therapies are able to …

Background Modulation of adaptive immunity may underscore the efficacy of trans-arterial
chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by …

Hepatocellular carcinoma (HCC) is the second cause of death due to malignancy in the
world, following lung cancer. The geographic distribution of this disease accompanies its …

Purpose To evaluate a fully automated machine learning algorithm that uses pretherapeutic
quantitative CT image features and clinical factors to predict hepatocellular carcinoma …

Treatment of hepatocellular carcinoma (HCC) is dependent on the stage of the disease.
Intermediate stage HCC encompasses the largest subgroup of patients with the disease …

Drug-eluting bead transarterial chemoembolization (DEB-TACE) is a relative new
endovascular treatment based on the use of microspheres to release chemotherapeutic …

Background & Aims Yttrium-90 transarterial radioembolization (TARE) has shown promising
efficacy in the treatment of patients with hepatocellular carcinoma (HCC), associated with …